文献速递骨显像与常规 SPECT核素与放射性配体治疗

170Tm-EDTMP:一种有望替代89SrCl2用于转移性骨痛诊疗的前瞻性选择

170Tm-EDTMP: A Prospective Alternative of 89SrCl2 for Theranostic Treatment of Metastatic Bone Pain.
PubMed 文献 · Clin Nucl Med · 2017-01-01

作者此前已报道170Tm-EDTMP作为骨痛姑息治疗中89SrCl2替代品的潜力,动物模型中的放射化学与生物学评价结果鼓舞了本临床研究的启动。

要点

  • 患者为68岁女性,乳腺癌骨转移,接受370 MBq(10 mCi)170Tm-EDTMP后行系列全身闪烁显像。
  • 作者此前报道170Tm-EDTMP是骨痛姑息治疗中89SrCl2的潜在低成本替代品。

核心结论

  • 作者此前报道170Tm-EDTMP具有作为89SrCl2低成本替代品用于骨痛姑息治疗的潜力,动物模型中的放射化学研究和生物学评价结果鼓舞了人体临床研究的启动。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We have earlier reported the potential of Tm-EDTMP as an alternative cost-effective radiopharmaceutical of SrCl2 for bone pain palliation application. Encouraging results obtained in the radiochemical studies and biological evaluations in animal model have prompted us to initiate the clinical study to evaluate the potential of Tm-EDTMP in human cancer patients. The serial scintigraphic images represent the whole-body scans of a patient (68 years old woman) with skeletal metastases of carcinoma of the breast origin recorded after administering 370 MBq (10 mCi) of Tm-EDTMP at different post-administration time points along with the pre-therapy images recorded with Tc-MDP in the same patient.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Das T, Shinto A, Kamaleshwaran KK, et al. 170Tm-EDTMP: A Prospective Alternative of 89SrCl2 for Theranostic Treatment of Metastatic Bone Pain. Clin Nucl Med. 2017. PMID: 28072622. doi:10.1097/RLU.0000000000001530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。